0001628280-21-012932.txt : 20210625
0001628280-21-012932.hdr.sgml : 20210625
20210625160325
ACCESSION NUMBER: 0001628280-21-012932
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210623
FILED AS OF DATE: 20210625
DATE AS OF CHANGE: 20210625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Meisner Derek M
CENTRAL INDEX KEY: 0001752461
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 211047677
MAIL ADDRESS:
STREET 1: C/O GENOCEA BIOSCIENCES, INC.
STREET 2: 100 ACORN PARK DRIVE, 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4
1
wf-form4_162465138910056.xml
FORM 4
X0306
4
2021-06-23
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0001752461
Meisner Derek M
C/O X4 PHARMACEUTICALS, INC.
61 NORTH BEACON STREET, 4TH FLOOR
BOSTON
MA
02134
0
1
0
0
General Counsel
Common Stock
2021-06-23
4
A
0
12500
0
A
85228
D
Common Stock
2021-06-24
4
S
0
4166
7
D
81062
D
Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on June 23, 2021. One third of the shares will vest on June 23, 2022, and one third of the shares will vest on June 23, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs.
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.86 to $7.28, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents unvested restricted stock units.
/s/ Derek M. Meisner
2021-06-25